Biotechnology company Thesan Pharmaceuticals raises $49m series B financing led by current investor Novo Ventures, and including Lundbeckfond Ventures and Novartis Venture Funds, to develop novel medicines for treating dermatological conditions such as acne.
Thesan Pharmaceuticals, a US-based biotechnology company focused on the treatment of dermatological conditions, including acne and atopic dermatitis, has raised $49m series B financing led by current investor Novo Ventures, the venture capital unit within the Novo group of life sciences companies owned by Denmark-based Novo Nordisk Foundation, with the participation of life sciences venture capital firm SV Life Sciences, Lundbeckfond Ventures, a life sciences venture fund owned by Denmark-based The Lundbeck Foundation, and Novartis Venture Funds, the corporate venturing…
